Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin

References

• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58
   PubMed Web of Science ®Google Scholar
• Si-Shen F, Shu C. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003;58:4087–114
   Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, et al. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity. Int J Pharm 2007;337:346–56
   PubMed Web of Science ®Google Scholar
• Aarif YK, Peter PL, Thomas F, et al. Cardiotoxicity due to cancer therapy. Cancer Heart 2011;38:253–9
   Web of Science ®Google Scholar
• Moorthi CR, Manavalan K, Kathiresan K. Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharmaceut Sci 2011;14:67–77
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771–82
   PubMed Web of Science ®Google Scholar
• Yogeshkumar M, Marilena L, Alexander MS. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30:592–9
   PubMed Web of Science ®Google Scholar
• Xiaowei D, Russell JM. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010;5:597–615
   PubMed Web of Science ®Google Scholar
• Frank G, Rohit K, Andrew W, et al. Targeted nanoparticles for cancer therapy. Nano Today 2007;2:14–21
   Web of Science ®Google Scholar
• Lara SJ, Lilian EV, Sunita Y, Mansoor MA. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008;34:592–602
   PubMed Web of Science ®Google Scholar
• Ruth D. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688–701
   PubMed Web of Science ®Google Scholar
• Chris O, Wouter B, Mariska B, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010;27:2569–89
   PubMed Web of Science ®Google Scholar
• Lilian EV, Mansoor MA. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006;3:205–16
   PubMedGoogle Scholar
• Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J Incl phenom macrocycl Chem 2013;75:315–22
   Web of Science ®Google Scholar
• Uchegbu IF, Double JA, Kelland LR, et al. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target 1996;3:399–409
   PubMed Web of Science ®Google Scholar
• John WP. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4:95–9
   PubMed Web of Science ®Google Scholar
• Carlotta M, Donatella P, Christian C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release 2010;147:127–35
   PubMed Web of Science ®Google Scholar
• Marzio LD, Marianecci C, Cinque B, et al. pH-sensitive non-phospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochim Biophys Acta 2008;1778:2749–56
   PubMed Web of Science ®Google Scholar
• Jain CP, Vyas SP. Preparation and characterization of niosomes containing rifampicin for lung targeting, J Microencapsul 1995;12:401–7
   PubMed Web of Science ®Google Scholar
• Pawar SK, Badhwar AJ, Kharas F, et al. Design, synthesis and evaluation of N-acetyl glucosamine (NAG)-PEG-doxorubicin targeted conjugates for anticancer delivery. Int J Pharm 2012;436:183–93
   PubMed Web of Science ®Google Scholar
• Johanna C, Christiane BH, Jacques P. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med 2010;14:771–94
   PubMed Web of Science ®Google Scholar
• Warburg O, Posener K, Negelein E. The metabolism of the carcinoma cell. In: Warburg O, ed. The metabolism of tumors. New York: Richard Smith, Inc.; 1931:29–169
   Google Scholar
• Taizo Y, Yutaka S, Hirofumi F, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223–30
   PubMed Web of Science ®Google Scholar
• Uchegbu IF. The biodistribution of novel 200 nm palmitoyl muramic acid vesicles. Int J Pharm 1998;162:19–27
   Web of Science ®Google Scholar
• Jianing Q, Ping Y, Fen H, et al. Nanoparticles with dextran/chitosan shell and BSA/chitosan core—doxorubicin loading and delivery. Int J Pharm 2010;393:176–84
   PubMed Web of Science ®Google Scholar
• Brownlie A, Uchegbu IF, Schatzlein AG. PEI-based vesicle–polymer hybrid gene delivery system with improved biocompatibility. Int J Pharm 2004;274:41–52
   PubMed Web of Science ®Google Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112–16
   PubMed Web of Science ®Google Scholar
• Rao MV, Atreyi M, Rajeswar MR. Fluorescence studies on concanavalin-A. J Biosci 1984;6:823–8
   Web of Science ®Google Scholar
• Froehlich P. Understanding the sensitivity specification of spectrofluorometers. Int Lab 1989;19:42–5
   Google Scholar
• Chipman DM, Grisaro V, Sharon N. The binding of oligosaccharides containing N-acetylglucosamine and N-acetylmuramic acid to lysozyme. The specificity of binding subsites. J Biol Chem 1967;242:4388–94
   PubMed Web of Science ®Google Scholar
• Wu G, Robertson DH, Brooks CL, Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 2003;24:1549–62
   PubMed Web of Science ®Google Scholar
• Glide, version 5.8, Schrödinger, LLC, New York, NY; 2012
   Google Scholar
• Maestro, version 9.3, Schrödinger, LLC, New York, NY; 2012
   Google Scholar
• Okimoto N, Futatsugi N, Fuji H, et al. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. PLoS Comput Biol 2009;5:1–12
   Web of Science ®Google Scholar
• Kandasamy R, Veintramuthu S. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 2010;11:1119–27
   PubMed Web of Science ®Google Scholar
• You HB, Kinam P. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release 2011;153:198–205
   PubMed Web of Science ®Google Scholar
• Sahin NO. Niosomes as nanocarrier systems. In: Mozafari MR, ed. Nanomaterials and nanosystems for biomedical applications. Netherlands: Springer; 2007:67–81
   Google Scholar
• Al-Hamidi H, Edwards AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B 2010;76:170–8
   PubMed Web of Science ®Google Scholar
• US2011/0243851. Glucose PEG conjugate for reducing glucose transport into the cell
   Google Scholar
• Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223–30
   PubMed Web of Science ®Google Scholar
• Schlick KH, Lange CK, Gillispie GD, Cloninger MJ. Characterization of protein aggregation via intrinsic fluorescence lifetime. J Am Chem Soc 2009;131:16608–9
   PubMed Web of Science ®Google Scholar
• Sha Z, Shiladitya B, William C, et al. Leucine–aspartic acid–valine sequence as targeting ligand and drug carrier for doxorubicin delivery to melanoma cells: in vitro cellular uptake and cytotoxicity studies. Pharmaceut Res 2009;26:2578–87
   PubMed Web of Science ®Google Scholar
• Dorit G, Aviva TH, Dina T, et al. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949–57
   PubMed Web of Science ®Google Scholar
• Eksborg S. Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: self-association in aqueous solution. J Pharm Sci 1978;67:782–5
   PubMed Web of Science ®Google Scholar
• Mennozi M, Valentini L, Vannini E, Arcamone F. Self-association of doxorubicin and related compounds in aqueous solution. J Pharm Sci 1984;73:766–70
   PubMed Web of Science ®Google Scholar
• Takafumi M, Eriko T, Yuji K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5
   PubMed Web of Science ®Google Scholar
• Raffaele C, Agnese V, Cristina R, et al. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Mol Cell Endocrinol 2008;291:57–62
   PubMed Web of Science ®Google Scholar
• Thomas AH, Robert BM, Richard AF, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
   PubMed Web of Science ®Google Scholar